SOURCE: Recordati S.p.A.

October 25, 2007 12:26 ET

Recordati S.p.A.: Positive First Nine Months 2007 Results, Sales and Margins Grow

MILAN, ITALY--(Marketwire - October 25, 2007) - - Consolidated revenue EUR 466.4 million, + 6.1%.

- Pharmaceutical revenue EUR 440.4 million, + 7.4%.

- International sales EUR 313.3 million, + 11.9%.

- Operating income EUR 100.9 million, + 9.7%.

- Net income EUR 64.0 million, + 14.5%.

- Net financial position* cash positive by EUR 22.3 million.

- Agreement signed for the acquisition of Orphan Europe.

The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first nine months 2007 prepared in accordance with the IAS/IFRS requirements for interim reporting (IAS 34).

First nine months financial highlights

- In the first nine months consolidated revenue is EUR 466.4 million, an jincrease of 6.1% over the same period of the preceding year. Pharmaceutical sales are EUR 440.4 million, an increase of 7.4% and include the Portuguese business acquired at the end of 2006. Pharmaceutical chemicals sales are EUR 26.0 million, down by 12.0%. International sales are EUR 313.3 million, an increase of 11.9%, and now represent 67.2% of total revenue. Sales in Italy are down by 4.0% mainly due to the price cuts imposed in the second half 2006.

- Operating income, at 21.6% of sales, is EUR 100.9 million, an increase of 9.7% over the first nine months of the preceding year. The operating margin improvement is mainly due to a higher gross margin and to the reduction in selling expenses, while R&D expenditure increased by 8.0%.

- Net income is EUR 64.0 million, an increase of 14.5% more than the increase in operating income due to an improved tax rate.

- The net financial position* at 30 September 2007 is cash positive by EUR 22.3 million, substantially unchanged from that at 31 December 2006. During the period dividends for an amount of EUR 37.0 million were paid out and own shares repurchased for a total cash outlay of EUR 29.9 million. Shareholders' equity increased and is EUR 367.8 million.

* Cash and short-term financial investments net of bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).

Business development news

- At the end of September an agreement was signed for the acquisition of Orphan Europe, a European pharmaceutical group with headquarters in Paris dedicated to the development, registration, marketing and distribution of unique drugs for the treatment of rare and orphan diseases. Orphan Europe employs about 120 personnel, and has subsidiaries in nine European countries and in the United Arab Emirates as well as representative offices in seven countries. Sales for the full year 2006 were EUR 40 million with EBIT of EUR 7.6 million. The company's net financial position is positive. The price to be paid at the closing, which is expected to take place before the end of 2007, is EUR 135 million. Orphan Europe currently markets ten products which target mostly chronic and life­-threatening diseases and has other high potential drugs in development. The orphan drug market is a niche market with significant growth potential. Only a few of the total estimated 6,000 to 8,000 rare diseases are currently treated pharmacologically. The identification and awareness of rare diseases is constantly increasing and the continuous scientific advances are enabling earlier diagnosis of these diseases and the development of adequate therapies.

- Zanipress®, our new antihypertensive product which associates lercanidipine and enalapril in a fixed combination, was launched in Germany in April by our subsidiary Merckle Recordati. This product was also launched by Meda, an international pharmaceutical company with which a non-exclusive co-marketing agreement was signed in February, as Zaneril®. In July the agreement with Meda was extended to the Spanish market as well. Furthermore, at the end of September the license agreement with Berlin Chemie (Menarini group) for the marketing of Carmen® (lercanidipine) in Germany was extended to the new combination product which will be launched in October as Carment ACE®.

- In January Recordati Ireland Ltd. initiated commercial operations in the Irish pharmaceutical market where Zanidip® (lercanidipine) is now promoted directly by this subsidiary following the termination of the agreement with the previous licensee. Furthermore, in April our subsidiary Recordati Hellas initiated sales of Lercadip® (lercanidipine) in Greece in both its 10 and 20mg dosage forms.

- In September the double-blind portion of the phase III study of silodosin, licensed from Kissei, was successfully completed. Silodosin is a new selective alpha blocker for the treatment of symptoms associated with benign hypertrophy of the prostate, a condition affecting millions of male patients across the world. The trial was conducted in 11 European countries with 1128 patients (977 randomized) enrolled in 70 clinical centres. The study was designed to show superiority of silodosin over placebo and non-inferiority to tamsulosin. Silodosin 8mg dosed once daily was found to be significantly superior to placebo in all parameters, with scores that were always equal to or better than those of tamsulosin. There were no safety issues. The drug is already on the market in Japan and has completed phase III studies in the US. Recordati is completing the long-term portion of the phase III study and plans to file for approval in Europe, and in other countries of the licensed territory, during the last quarter of 2008.

- At the end of May Jaba Recordati transferred its industrial lease agreement for the production site in Loures, Portugal, and the associated pharmaceutical manufacturing business to Clintex Produtos Farmacêuticos for an amount of EUR 1.8 million which includes the value of existing inventories.

Management comments

"During the third quarter we announced positive outcomes from the phase III study of silodosin and signed an agreement for the acquisition of Orphan Europe, two important steps for the future development of our group" declared Giovanni Recordati, Chairman and CEO. "Our international business continues to drive growth which supports our expansion strategy. During the first nine months of the year profitability has improved both on an operating as well as net income level, and this allows us to confirm our full year operating income and net income targets of EUR 132 million and EUR 83 million respectively, with net sales of around EUR 630 million."

Conference call

Recordati will be hosting a conference call tomorrow 26 October 2007 at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). Dial-in numbers are:

Italy +39 02 802 09 11

UK +44 208 7929 750

USA +1 866 2396 425

France +33 170 700 532

Germany +49 69 2222 2225

A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.

Callers are invited to dial-in 10 minutes before conference time and ask for the Recordati conference call. If conference operator assistance is required during the connection please digit * followed by 0. A recording (Real Audio file) of the conference call will be placed on the website www.recordati.com.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,200. A European field force of over 1,100 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2006 was EUR 576.2 million, operating income was EUR 120.3 million and net income was EUR 74.0 million.

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of EUR )

+-------------------------+-----------------+-----------------+----------+
|INCOME STATEMENT         |  Jan – Sept 2007|  Jan – Sept 2006|  Change %|
+-------------------------+-----------------+-----------------+----------+
|REVENUE                  |          466,407|          439,566|       6.1|
+-------------------------+-----------------+-----------------+----------+
|Cost of sales            |        (150,452)|        (144,823)|       3.9|
+-------------------------+-----------------+-----------------+----------+
|GROSS PROFIT             |          315,955|          294,743|       7.2|
+-------------------------+-----------------+-----------------+----------+
|Selling expenses         |        (150,955)|        (147,463)|       2.4|
+-------------------------+-----------------+-----------------+----------+
|Research and development |         (36,867)|         (34,140)|       8.0|
|expenses                 |                 |                 |          |
+-------------------------+-----------------+-----------------+----------+
|General & administrative |         (24,667)|         (20,256)|      21.8|
|expenses                 |                 |                 |          |
+-------------------------+-----------------+-----------------+----------+
|Other income (expenses), |          (2,569)|            (899)|     185.8|
|net                      |                 |                 |          |
+-------------------------+-----------------+-----------------+----------+
|OPERATING INCOME         |          100,897|           91,985|       9.7|
+-------------------------+-----------------+-----------------+----------+
|Financial income         |          (3,127)|          (1.805)|      73.2|
|(expenses), net          |                 |                 |          |
+-------------------------+-----------------+-----------------+----------+
|PRETAX INCOME            |           97,770|           90,180|       8.4|
+-------------------------+-----------------+-----------------+----------+
|Provision for income     |         (33,733)|         (34,258)|     (1.5)|
|taxes                    |                 |                 |          |
+-------------------------+-----------------+-----------------+----------+
|NET INCOME               |           64,037|           55,922|      14.5|
+-------------------------+-----------------+-----------------+----------+
+--------------------+-----------------+-----------------+----------+
|  EARNINGS PER SHARE|  Jan – Sept 2007|  Jan – Sept 2006|  Change %|
+--------------------+-----------------+-----------------+----------+
|  Basic             |          € 0.321|          € 0.279|      15.1|
+--------------------+-----------------+-----------------+----------+
|  Diluted           |          € 0.313|          € 0.271|      15.5|
+--------------------+-----------------+-----------------+----------+
+--------------------+-----------------+-----------------+----------+
Earnings per share (EPS) are based on average shares outstanding during each year, 199,428,481 in 2007 and 200,195,116 in 2006, net of average treasury stock which amounted to 7,452,602 in 2007 and 5,405,059 in 2006. Diluted earnings per share is calculated taking into account new shares authorized but not yet issued.
+-------------------------+-----------------+-----------------+----------+
|COMPOSITION OF REVENUE   |  Jan – Sept 2007|  Jan – Sept 2006|  Change %|
+-------------------------+-----------------+-----------------+----------+
|Pharmaceuticals          |          440,378|          409,991|       7.4|
+-------------------------+-----------------+-----------------+----------+
| Pharmaceutical chemicals|           26,029|           29,575|    (12.0)|
+-------------------------+-----------------+-----------------+----------+
|TOTAL                    |          466,407|          159,532|       6.1|
+-------------------------+-----------------+-----------------+----------+
| - of which International|          313,262|          280,034|      11.9|
+-------------------------+-----------------+-----------------+----------+
+-------------------------+-----------------+-----------------+----------+

RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of EUR )

+-------------------------+---------------+---------------+----------+
|INCOME STATEMENT         |  Third Quarter|  Third Quarter|  Change %|
+-------------------------+---------------+---------------+----------+
|                         |           2007|           2006|          |
+-------------------------+---------------+---------------+----------+
|REVENUE                  |        145,909|        128,485|      13.6|
+-------------------------+---------------+---------------+----------+
|Cost of sales            |       (47,094)|       (42,623)|      10.5|
+-------------------------+---------------+---------------+----------+
|GROSS PROFIT             |         98,815|         85,862|      15.1|
+-------------------------+---------------+---------------+----------+
|Selling expenses         |       (47,089)|       (40,225)|      17.1|
+-------------------------+---------------+---------------+----------+
|Research and development |       (11,856)|       (10,772)|      10.1|
|expenses                 |               |               |          |
+-------------------------+---------------+---------------+----------+
|General & administrative |        (7,422)|        (6,260)|      18.6|
|expenses                 |               |               |          |
+-------------------------+---------------+---------------+----------+
|Other income (expenses), |        (1,179)|          (208)|     466.8|
|net                      |               |               |          |
+-------------------------+---------------+---------------+----------+
|OPERATING INCOME         |         31,269|         28,397|      10.1|
+-------------------------+---------------+---------------+----------+
|Financial income         |        (2,229)|          (472)|     372.2|
|(expenses), net          |               |               |          |
+-------------------------+---------------+---------------+----------+
|PRETAX INCOME            |         29,040|         27,925|       4.0|
+-------------------------+---------------+---------------+----------+
|Provision for income     |        (9,938)|        (9,427)|       5.4|
|taxes                    |               |               |          |
+-------------------------+---------------+---------------+----------+
|NET INCOME               |         19,102|         18,498|       3.3|
+-------------------------+---------------+---------------+----------+
+-------------------------+---------------+---------------+----------+
|COMPOSITION OF REVENUE   |  Third Quarter|  Third Quarter|  Change %|
+-------------------------+---------------+---------------+----------+
|                         |           2007|           2006|          |
+-------------------------+---------------+---------------+----------+
|Pharmaceuticals          |        139,063|        120,652|      15.3|
+-------------------------+---------------+---------------+----------+
| Pharmaceutical chemicals|          6,846|          7,833|    (12.6)|
+-------------------------+---------------+---------------+----------+
|TOTAL                    |        145,909|        128,485|      13.6|
+-------------------------+---------------+---------------+----------+
| - of which International|        100,073|         87,653|      14.2|
+-------------------------+---------------+---------------+----------+
+-------------------------+---------------+---------------+----------+
RECORDATI GROUP

Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)

(thousands of EUR )

+-------------------------+------------+------------+
|ASSETS                   |  30.09.2007|  31.12.2006|
+-------------------------+------------+------------+
|Property, plant and      |      66,436|      71,916|
|equipment                |            |            |
+-------------------------+------------+------------+
|Intangible assets        |      85,272|      92,490|
+-------------------------+------------+------------+
|Goodwill                 |     130,228|     129,771|
+-------------------------+------------+------------+
|Equity investments       |         511|         696|
+-------------------------+------------+------------+
|Non-current receivables  |       1,110|       1,268|
+-------------------------+------------+------------+
|Deferred tax assets      |      20,504|      18,798|
+-------------------------+------------+------------+
|TOTAL NON-CURRENT ASSETS |     304,061|     314,939|
+-------------------------+------------+------------+
|Inventories              |      78,227|      74,670|
+-------------------------+------------+------------+
|Trade receivables        |     115,721|     123,418|
+-------------------------+------------+------------+
|Other receivables        |       8,665|      11,002|
+-------------------------+------------+------------+
|Other current assets     |       4,089|       1,789|
+-------------------------+------------+------------+
|Short-term financial     |     114,903|     145,029|
|investments, cash and    |            |            |
|cash equivalents         |            |            |
+-------------------------+------------+------------+
|TOTAL CURRENT ASSETS     |     321,605|     355,908|
+-------------------------+------------+------------+

|TOTAL ASSETS             |     625,666|     670,847|
+-------------------------+------------+------------+
+-------------------------+------------+------------+
|EQUITY AND LIABILITIES   |  30.09.2007|  31.12.2006|
+-------------------------+------------+------------+
|Share capital            |      25,926|      25,802|
+-------------------------+------------+------------+
|Capital in excess of par |      77,092|      73,165|
|value                    |            |            |
+-------------------------+------------+------------+
|Treasury stock           |    (60,200)|    (30,653)|
+-------------------------+------------+------------+
|Hedging reserve          |       (267)|     (1,081)|
+-------------------------+------------+------------+
|Translation reserve      |     (1,756)|         336|
+-------------------------+------------+------------+
|Other reserves           |      25,274|      24,926|
+-------------------------+------------+------------+
|Retained earnings        |     237,740|     200,276|
+-------------------------+------------+------------+
|Net income for the year  |      64,037|      74,031|
+-------------------------+------------+------------+
|SHAREHOLDERS’ EQUITY     |     367,846|     366,802|
+-------------------------+------------+------------+
|Loans due after one year |      77,787|      83,697|
+-------------------------+------------+------------+
|Employees’ termination   |      22,093|      22,587|
|pay                      |            |            |
+-------------------------+------------+------------+
|Deferred tax liabilities |       9,982|       9,402|
+-------------------------+------------+------------+
|Other non-current        |           0|       5,645|
|liabilities              |            |            |
+-------------------------+------------+------------+
|TOTAL NON-CURRENT        |     109,862|     121,331|
|LIABILITIES              |            |            |
+-------------------------+------------+------------+
|Trade payables           |      64,106|      71,537|
+-------------------------+------------+------------+
|Other payables           |      33,496|      32,159|
+-------------------------+------------+------------+
|Tax liabilities          |      22,607|      22,076|
+-------------------------+------------+------------+
|Other current liabilities|         385|         413|
+-------------------------+------------+------------+
|Provisions               |      12,322|      16,479|
+-------------------------+------------+------------+
|Change in fair value of  |         267|       1,081|
|hedging derivatives (cash|            |            |
|flow hedge)              |            |            |
+-------------------------+------------+------------+
|Change in fair value of  |       7,363|       3,949|
|hedging derivatives (fair|            |            |
|value hedge)             |            |            |
+-------------------------+------------+------------+
|Loans due within one year|       3,354|      20,446|
+-------------------------+------------+------------+
|Bank overdrafts          |       4,058|      14,574|
+-------------------------+------------+------------+
|TOTAL CURRENT LIABILITIES|     147,958|     182,714|
+-------------------------+------------+------------+
|TOTAL EQUITY AND         |     625,666|     670,847|
|LIABILITIES              |            |            |
+-------------------------+------------+------------+

DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS

The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.

This information is provided by CompanynewsGroup

Contact Information